Real-world Medicare Healthcare Costs of Patients with Dupuytren’s Contracture Treated with Collagenase or Fasciectomy

Background:. Our study aimed to compare real-world healthcare resource utilization (HRU) and healthcare cost (HC) of Medicare-insured patients (≥65 years old) with Dupuytren’s contracture (DC) treated with Clostridium histolyticum (collagenase) or fasciectomy. Methods:. DC patients treated with coll...

Full description

Bibliographic Details
Main Authors: Vladimir Zah, DPhil, Filip Stanicic, MSc, Jane Ruby, PhD, Djurdja Vukicevic, MD, PhD, David Hurley, MD
Format: Article
Language:English
Published: Wolters Kluwer 2022-08-01
Series:Plastic and Reconstructive Surgery, Global Open
Online Access:http://journals.lww.com/prsgo/fulltext/10.1097/GOX.0000000000004480
_version_ 1817997850579042304
author Vladimir Zah, DPhil
Filip Stanicic, MSc
Jane Ruby, PhD
Djurdja Vukicevic, MD, PhD
David Hurley, MD
author_facet Vladimir Zah, DPhil
Filip Stanicic, MSc
Jane Ruby, PhD
Djurdja Vukicevic, MD, PhD
David Hurley, MD
author_sort Vladimir Zah, DPhil
collection DOAJ
description Background:. Our study aimed to compare real-world healthcare resource utilization (HRU) and healthcare cost (HC) of Medicare-insured patients (≥65 years old) with Dupuytren’s contracture (DC) treated with Clostridium histolyticum (collagenase) or fasciectomy. Methods:. DC patients treated with collagenase or fasciectomy between July 2011 and June 2017 were identified using the IBM MarketScan Medicare Supplemental Database. The index date was the date of the first procedure. Demographic characteristics were captured on the index date, and comorbidities were assessed during the 24-month preindex period. HRU and HC were analyzed throughout the 12-month postindex period. Patients were matched using propensity score weights. Gamma log-linked generalized linear models were used to evaluate HC drivers. Results:. Out of 37,374 DC patients, 2911 received collagenase, while 6258 underwent fasciectomy. Postmatching, the total average annual HC was similar between collagenase and fasciectomy ($7271 versus $6220, P = 0.357). When HCs were stratified by the service provider, outpatient facility and physician office costs were lower in the collagenase cohort ($850 versus $1284, P = 0.047 and $546 versus $1001, P < 0.001). The costs of professional services were significantly higher than in the fasciectomy cohort due to the cost of collagenase injection ($1682 versus $629, P < 0.001). The HRU was similar between cohorts, except for more frequent outpatient facility visits in fasciectomy patients (12.3 versus 22.9, P < 0.001). Generalized linear model revealed Charlson comorbidity index, plan type, patients’ residence region, sleep disorder, and hyperlipidemia as significant predictors of total HC. Conclusion:. This study found comparable total annual HC and HRU between collagenase- and fasciectomy-treated Medicare patients.
first_indexed 2024-04-14T02:44:23Z
format Article
id doaj.art-2e9d2ea2fddb41af9253d4daf6f80645
institution Directory Open Access Journal
issn 2169-7574
language English
last_indexed 2024-04-14T02:44:23Z
publishDate 2022-08-01
publisher Wolters Kluwer
record_format Article
series Plastic and Reconstructive Surgery, Global Open
spelling doaj.art-2e9d2ea2fddb41af9253d4daf6f806452022-12-22T02:16:37ZengWolters KluwerPlastic and Reconstructive Surgery, Global Open2169-75742022-08-01108e448010.1097/GOX.0000000000004480202208000-00011Real-world Medicare Healthcare Costs of Patients with Dupuytren’s Contracture Treated with Collagenase or FasciectomyVladimir Zah, DPhil0Filip Stanicic, MSc1Jane Ruby, PhD2Djurdja Vukicevic, MD, PhD3David Hurley, MD4From the * HOER Department, ZRx Outcomes Research Inc., Mississauga, Ontario, CanadaFrom the * HOER Department, ZRx Outcomes Research Inc., Mississauga, Ontario, Canada† Medical Department, Endo Pharmaceuticals Inc., Malvern, Pa.From the * HOER Department, ZRx Outcomes Research Inc., Mississauga, Ontario, Canada† Medical Department, Endo Pharmaceuticals Inc., Malvern, Pa.Background:. Our study aimed to compare real-world healthcare resource utilization (HRU) and healthcare cost (HC) of Medicare-insured patients (≥65 years old) with Dupuytren’s contracture (DC) treated with Clostridium histolyticum (collagenase) or fasciectomy. Methods:. DC patients treated with collagenase or fasciectomy between July 2011 and June 2017 were identified using the IBM MarketScan Medicare Supplemental Database. The index date was the date of the first procedure. Demographic characteristics were captured on the index date, and comorbidities were assessed during the 24-month preindex period. HRU and HC were analyzed throughout the 12-month postindex period. Patients were matched using propensity score weights. Gamma log-linked generalized linear models were used to evaluate HC drivers. Results:. Out of 37,374 DC patients, 2911 received collagenase, while 6258 underwent fasciectomy. Postmatching, the total average annual HC was similar between collagenase and fasciectomy ($7271 versus $6220, P = 0.357). When HCs were stratified by the service provider, outpatient facility and physician office costs were lower in the collagenase cohort ($850 versus $1284, P = 0.047 and $546 versus $1001, P < 0.001). The costs of professional services were significantly higher than in the fasciectomy cohort due to the cost of collagenase injection ($1682 versus $629, P < 0.001). The HRU was similar between cohorts, except for more frequent outpatient facility visits in fasciectomy patients (12.3 versus 22.9, P < 0.001). Generalized linear model revealed Charlson comorbidity index, plan type, patients’ residence region, sleep disorder, and hyperlipidemia as significant predictors of total HC. Conclusion:. This study found comparable total annual HC and HRU between collagenase- and fasciectomy-treated Medicare patients.http://journals.lww.com/prsgo/fulltext/10.1097/GOX.0000000000004480
spellingShingle Vladimir Zah, DPhil
Filip Stanicic, MSc
Jane Ruby, PhD
Djurdja Vukicevic, MD, PhD
David Hurley, MD
Real-world Medicare Healthcare Costs of Patients with Dupuytren’s Contracture Treated with Collagenase or Fasciectomy
Plastic and Reconstructive Surgery, Global Open
title Real-world Medicare Healthcare Costs of Patients with Dupuytren’s Contracture Treated with Collagenase or Fasciectomy
title_full Real-world Medicare Healthcare Costs of Patients with Dupuytren’s Contracture Treated with Collagenase or Fasciectomy
title_fullStr Real-world Medicare Healthcare Costs of Patients with Dupuytren’s Contracture Treated with Collagenase or Fasciectomy
title_full_unstemmed Real-world Medicare Healthcare Costs of Patients with Dupuytren’s Contracture Treated with Collagenase or Fasciectomy
title_short Real-world Medicare Healthcare Costs of Patients with Dupuytren’s Contracture Treated with Collagenase or Fasciectomy
title_sort real world medicare healthcare costs of patients with dupuytren s contracture treated with collagenase or fasciectomy
url http://journals.lww.com/prsgo/fulltext/10.1097/GOX.0000000000004480
work_keys_str_mv AT vladimirzahdphil realworldmedicarehealthcarecostsofpatientswithdupuytrenscontracturetreatedwithcollagenaseorfasciectomy
AT filipstanicicmsc realworldmedicarehealthcarecostsofpatientswithdupuytrenscontracturetreatedwithcollagenaseorfasciectomy
AT janerubyphd realworldmedicarehealthcarecostsofpatientswithdupuytrenscontracturetreatedwithcollagenaseorfasciectomy
AT djurdjavukicevicmdphd realworldmedicarehealthcarecostsofpatientswithdupuytrenscontracturetreatedwithcollagenaseorfasciectomy
AT davidhurleymd realworldmedicarehealthcarecostsofpatientswithdupuytrenscontracturetreatedwithcollagenaseorfasciectomy